Membership information 0800 225 677
Medicolegal advice 0800 982 766

Prescribing of Ivermectin in COVID-19 treatment

19 February 2021
On 28 January 2021 SAHPRA implemented an Ivermectin controlled compassionate use programme under Section 21 of the Medicines and Related Substances Act, relating to the prescribing of Ivermectin in the management of COVID-19.

Although Medical Protection would not ordinarily extend the right to request assistance to matters arising from the use of unregistered drugs such as Ivermectin, we recognise the extraordinary situation that has arisen as a result of COVID-19, and following the implementation of the Section 21 process for this drug by SAHPRA, can confirm that where our individual patient notification and Ivermectin prescribing  requirements are met, members will have the right to request assistance for matters arising from the prescribing of Ivermectin.

If a member is intending to prescribe Ivermectin to an individual patient – pursuant to a Section 21 application – they must contact Medical Protection within 7 days of receiving SAHPRA approval: advising us of the SAHPRA reference number and date of approval. This should be done via our online notification form which can be found here.

Once we have received the notification, a confirmation email will be sent to the member when the notification has been processed. This may take up to 3 working days. There is no need for the member to wait for our confirmation before prescribing Ivermectin, as they will have already been granted Section 21 authorisation.

If members have already obtained Section 21 authorisations, we ask that they contact us to retrospectively notify us of the SAHPRA reference number[s] and date of approval[s].

Information on SAHPRA’s stance on Ivermectin prescribing is available here:

You can find answers to common questions relating to the use of Ivermectin and your Medical Protection membership here